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Background: Patients with large prostate volumes have been shown to have higher rates of genitourinary and
gastrointestinal toxicities after conventional radiation therapy for prostate cancer. The efficacy and toxicity of
stereotactic body radiation therapy (SBRT), which delivers fewer high-dose fractions of radiation treatment, is unknown
for large prostate volume prostate cancer patients. We report our early experience using SBRT for localized prostate
cancer in patients with large prostate volumes.
Methods: 57 patients with prostate volumes ≥50 cm3 prior to treatment with SBRT for localized prostate carcinoma
and with a minimum follow up of two years were included in this retrospective review of prospectively collected data.
Treatment was delivered using Cyberknife (Accuray) with doses of 35–36.25 Gy in 5 fractions. Biochemical control was
assessed using the Phoenix definition. Toxicities were scored using the CTCAE v.4. Quality of life was assessed using the
American Urological Association (AUA) Symptom Score and the Expanded Prostate Cancer Index Composite (EPIC)-26.
Results: 57 patients (23 low-, 25 intermediate- and 9 high-risk according to the D’Amico classification) at a median age
of 69 years (range, 54–83 years) received SBRT with a median follow-up of 2.9 years. The median prostate size was
62.9 cm3 (range 50–138.7 cm3). 33.3% of patients received ADT. The median pre-treatment prostate-specific antigen
(PSA) was 6.5 ng/ml and decreased to a median PSA of 0.4 ng/ml by 2 years (p <0.0001). A mean baseline AUA symptom
score of 7.5 significantly increased to 13 at 1 month (p = 0.001) and returned to baseline by 3 months (p = 0.21). 23% of
patients experienced a late transient urinary symptom flare in the first two years following treatment. Mean baseline
EPIC bowel scores of 95.8 decreased to 78.1 at 1 month (p <0.0001), but subsequently improved to 93.5 three months
(p = 0.08). The 2-year actuarial incidence rates of GU and GI toxicity≥ grade 2 were 49.1% and 1.8%, respectively. Two
patients (3.5%) experienced grade 3 urinary toxicity, and no patient experienced grade 3 gastrointestinal toxicity.
Conclusions: SBRT for clinically localized prostate cancer was well tolerated in men with large prostate volumes.
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External beam radiation therapy (EBRT) and brachyther-
apy are the primary radiation modalities for clinically
localized prostate cancer. Over the last few decades, ex-
ternal beam radiation delivery has evolved from 2-D de-
livery to 3-D conformal and, subsequently, to IMRT and
stereotactic body radiation therapy (SBRT). These ad-
vances in radiation treatment planning and radiation
delivery have allowed for higher doses of radiation to be
delivered, thereby improving biochemical progression
free survival [1-4] and reducing the rates of salvage
therapy in high risk patients [5]. For men with localized
prostate cancer, the typical treatment with dose-escalated
EBRT involves fractionated radiation therapy, using daily
doses of 1.8-2.0 Gy for eight to nine weeks. SBRT delivers
fewer, high-dose fractions of radiation, providing a number
of advantages, including a more convenient, shortened
time course as well as a theoretical improvement in cancer
response to larger daily radiation fractions [6]. Early data
from trials of SBRT show SBRT to be comparably effective
in prostate cancer treatment [7-15].
Brachytherapy, which involves placing radioactive sources
into prostate tissue, is another radiation treatment option
for patients who prefer an abbreviated course of treatment,
either as a single modality in low risk patients or in com-
bination with external beam therapy in intermediate and
high risk patients [16,17]. However, brachytherapy is not
appropriate for all patients, including patients with unfavor-
able anatomy [18], including pubic arch interference, those
who cannot tolerate anesthesia, patients with significant
medical co-morbidities, or those who are at increased risk
for treatment-related complications. For instance, patients
with a history of prior TURP treatment or with baseline
urinary obstructive symptoms and/or large prostate sizes
(>50 cc) are considered to be at an increased risk for urin-
ary incontinence or urinary obstruction respectively. In-
deed, the relationship between acute toxicity and large
prostate size has been reported for brachytherapy [19-23],
although one study has shown that biochemical control
and acceptable late toxicities may be achieved in patients
presenting with large volume prostates [24]. Some patients
with large prostates may become candidates for brachyther-
apy with neoadjuvant androgen deprivation therapy (ADT)
to shrink the prostate; however, this is achieved at the
expense of toxicities of hormone therapy, including hot
flashes, loss of libido, obesity, osteoporosis, and risk for dia-
betes and cardiovascular disease [25].
Acute toxicity associated with external beam radiation
commonly involves the genitourinary and gastrointes-
tinal systems, including irritative or obstructive urinary
dysfunction and bowel frequency and urgency [26]. Ad-
vances in external beam radiation technique [27-29] and
utilization of daily prostate localization with IGRT [30]
have been shown to reduce the rates of toxicity. Like inbrachytherapy, another factor that impacts the develop-
ment of external beam radiation-induced toxicity is the
volume of the prostate. The link between prostate vol-
ume and increasing acute radiation toxicity has been
well described following 3-D conformal radiation [26,31]
and IMRT [32].
While early data from SBRT shows a comparable tox-
icity profile to that of IMRT, the efficacy and toxicity of
SBRT for prostate cancer patients with large prostate
volumes remain unclear. The purpose of this study was
to evaluate the influence of prostate volume on acute
and late urinary and bowel toxicity in patients treated
with SBRT.
Methods
This study is a retrospective review of prospectively
collected data on 57 consecutively treated patients with
prostate volumes ≥50 cm3, who received hypofractionated
stereotactic body radiotherapy at Medstar-Georgetown
University Hospital as monotherapy for histologically-
confirmed localized prostate cancer. Risk category was de-
fined using the D’Amico classification [16]. Clinical stage
was assigned according to the 6th edition of the American
Joint Committee on Cancer definitions. Exclusion criteria
included less than two years of clinical follow-up, clinical
involvement of lymph nodes, distant metastases on pre-
treatment imaging, prior prostate cancer-directed therapy,
or prior pelvic irradiation. Institutional review board ap-
proval was obtained for this analysis.
Treatment planning and delivery
Prior to treatment planning, 4 gold fiducials were placed
into the prostate. Approximately seven days after fiducial
placement, patients underwent MR imaging followed
shortly thereafter by a thin-cut CT scan. Fused CT and
MR images were then used for treatment planning. The
fiducial placement and CT/MRI simulation procedures
have been previously described [33]. The gross tumor
volume (GTV) was defined as the prostatic capsule and
the proximal seminal vesicles up to the point that the
left and right seminal vesicles separated. The GTV was
then further expanded by 3 mm posteriorly and 5 mm
in all other directions to create a CTV. No further
expansion was made from CTV to PTV. Treatment
planning was performed using Multiplan (Accuray Inc.,
Sunnyvale, CA). Figure 1a shows an axial view of a typ-
ical treatment plan. 35–36.25 Gy was given to the PTV
in 5 fractions over 2 weeks to a mean prescription iso-
dose line of 77%. The rectum, bladder, testes, penile bulb
and membranous urethra and prostatic urethra were
contoured and evaluated with a dose-volume histo-
gram. A typical dose volume histogram is shown in Figure 1b.
Dose constraints have been previously reported [7].
Target position was verified every 30–60 seconds during
Figure 1 Treatment Planning and Delivery. (a) The volumes represent the GTV (red), PTV (blue), rectum (light green), and bladder (yellow).
The prescription isodose line (82%) is denoted by the thick cyan line. (b) A typical dose-volume histogram (DVH) for Cyberknife treatment of a
prostate cancer patient is shown, revealing doses to the GTV, PTV, and nearby critical structures, including the rectum, bladder, and penile bulb.
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described [33,34].
Pretreatment assessment and follow-up
Prostate volume assessment was either performed by the
patient’s treating urologist at the time of biopsy and/or
at our institution during fiducial placement. In addition,
patient assessments included clinical examination, a
digital rectal exam, PSA level, and a quality of life
(QOL) questionnaire. These assessments were per-
formed prior to the initiation of stereotactic body radio-
therapy, at 1 and 3 months post-treatment, and every
3 months thereafter. Biochemical failure was defined as
a PSA rise of ≥2 ng/mL above the nadir [35]. Acute and
late toxicities were scored using the Common Termin-
ology Criteria for Adverse Events (CTCAE) Version 4.0.
Toxicity is defined as acute, occurring within 6 months
of completing treatment, and late reflecting those events
occurring later than 6 months. At each follow-up visit,
toxicity events were scored independently for each of
the different toxicity types, and the highest GU and GI
toxicities were determined for each patient. The QOL
questionnaires evaluated urinary, bowel, and erectile
functions using the American Urological Association
Symptom Score (AUA) [36], the Expanded Prostate Can-
cer Index Composite (EPIC) short form [37], and the
12-item Medical Outcomes Study Short Form (SF-12)
version 2 questionnaires [38]. Late urinary symptom
flare was defined as having both an AUA score ≥15 with
an increase of ≥5 points above baseline six months after
the completion of SBRT.
Statistical analysis
Student’s t-test and chi-square analysis were used to as-
sess differences in ongoing PSA and quality of life scores
in comparison to baseline. As previously reported, lateurinary symptom flare was defined as an increase of ≥5
points above baseline with a degree of severity in the
moderate to severe range (AUA score ≥15) [39]. The
flare was considered resolved when either the AUA
score dropped to <15 or the score returned to <5 points
above the patient’s pre-treatment baseline. QOL data
from time points in which more than 80% of patients
completed the questionnaires were included in the ana-
lysis. A QOL change of one-half standard deviation (SD)
from the baseline QOL score, defined as the minimal
important difference (MID), was used to denote a
clinically significant change in the QOL score [40]. The
two-sided paired Wilcoxon rank-sum test was used to
calculate the significance of differences in the mean
scores on follow-up as compared to the baseline values.
Parameters were identified as significant if the two-tailed
p-value was less than 0.05. MedCalc® version 11.6.1.0
was used for the statistical analyses.
Results
Fifty-seven men, who met the inclusion criteria, were
treated at our institution between August 2008 and May
2011, with a median clinical follow-up of 2.9 years
(range, 1.9-3.6 years). The median prostate size was
62.9 cm3 (range 50–138.7 cm3). Their baseline charac-
teristics are summarized in Table 1. Of note, our patients
were 54% Caucasian with a median age of 69 years old
(range, 54–83 years). By D’Amico classification, 23 were
low-, 25 intermediate-, and 9 high risk. 33.3% of our
patients received androgen deprivation therapy as pre-
scribed by their urologist for either combined modality
prostate cancer treatment or management of urinary
symptoms. 78.9% of patients were treated with 36.25 Gy
and 19.3% of patients were treated with 35 Gy.
The median pre-treatment PSA was 6.5 ng/mL (0.2-24 ng/
mL), and, at 2 years, the median PSA decreased to 0.4 ng/mL
Table 1 Patient characteristics
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chemical failure, occurring in an intermediate risk patient,
who was found to have widely metastatic disease to the
bone 12 months post-treatment. The overall two-year ac-
tuarial biochemical relapse free survival was 98%.
Baseline quality of life demographics for our patients
are shown in Table 2. Pre-treatment EPIC results revealthat our patient population had baseline mild-moderate
urinary incontinence (score 86.4) and irritative/obstruct-
ive (score 86) symptoms. The low sexual function scores
may be partially related to the 33.3% use of androgen
deprivation therapy. Pre-treatment AUA scores correlate
with the findings on EPIC, revealing that the majority of
our treatment population had either mild (49.1%) or
moderate (43.9%) baseline urinary bother, with the mean
AUA score being 9.1 ± 6.6 (range, 0–33). Baseline SF-12
scores for our patient group were comparable to those
of a similarly aged general population.
The prevalence of GU and GI toxicities following
treatment is shown in Table 3. The prevalence of single
symptoms as well as the highest GI and GU toxicity per
patient are depicted independently for each follow-up
visit. Actuarial incidence rates of late grade 2 and 3 GU
toxicities are shown in Figure 3a. 49.1% of patients
experienced grade 2 urinary toxicities, requiring initi-
ation or increase in alpha antagonist medications.
Urinary grade 3 toxicities were low, being observed in
3.5% of patients, with one patient developing grade 3
retention at 12 months requiring a TURP and another
patient developing grade 3 hematuria at 6 months re-
quiring cauterization.
Analyses of urinary function health related quality of
life are shown in Figures 3b-f. Evaluation of AUA score
(Figure 3b) reveals two distinct peaks at 1 month and
9 months post-treatment. A mean baseline AUA symp-
tom score of 7.5 significantly increased to 13 at 1 month
(p = 0.001) and returned to baseline at 3 months (p = 0.21).
Another small peak was seen between 6 to 9 months,
where the mean AUA went from 9 to 9.7. Indeed, 23% of
patients experienced a late transient urinary symptom flare
(≥6 months after completing treatment) in the first two
years following treatment (Figure 3c), with the median time
to flare being 9 months and the median duration of flare
being 3 months. As shown in Figure 3d, at baseline, 37% of
patients reported using alpha antagonists pre-treatment.
New or increased alpha antagonist use, graded as a grade 2
toxicity (Table 3), correlated with the increased AUA score
and peaked at 1 month, with 67% of patients requiring
change or initiation of alpha antagonist medications. An-
other small increase in alpha antagonist use was seen from
6 to 9 months post-treatment, also correlating with the sec-
ond increased AUA score. At 24 months alpha antagonist
use was higher than baseline but significantly decreased
from the peak of 1 month, with 48% of patients reporting
use at two years. Analysis of the changes in EPIC scores
(Figures 3e-f) also showed two significant dips at 1 month
and at 9 months. As shown in Figure 3e, mean baseline
EPIC urinary obstructive scores of 86 significantly de-
creased to 75.5 at one month (p <0.0002), but subsequently
improved to 84 at 3 months (p = 0.39). Another transient
decrease in EPIC scores occurred at 9 months, with
Figure 2 Median PSA changes. The median pre-treatment prostate-specific antigen (PSA) was 6.5 ng/ml, and, at 2 years, the median PSA
decreased to 0.4 ng/ml (p < 0.0001).
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(p <0.008). EPIC urinary obstructive scores subsequently
improved back to baseline at 12 months (p = 0.13) and
remained stable, with the 2 year score being 87.4. The mean
baseline EPIC urinary incontinence score of 86.1 (Figure 3f)
was not significantly changed throughout the 2 year post-
treatment follow up.
Actuarial incidence rates of late grade 2 and 3 GI toxic-
ities are shown in Figure 4a. A grade 2 GI toxicity of in-
creased frequency of bowel movements was seen in one
patient (1.8%); there were no grade 3 gastrointestinal
toxicities. The bowel quality of life scores are shown in
Figure 4b. The mean EPIC bowel score of 95.8 signifi-
cantly decreased to 78.1 at 1 month (p <0.0001), butTable 2 Baseline QOL characteristics







PCS (n = 56) 48.9 (22.1-63.1)
MCS (n = 56) 56.7 (31.1-65.9)
Baseline AUA Score Patient No. (% patients)
0-7 (mild) 28 (49.1%)
8-19 (moderate) 25 (43.9%)
≥20 3 (5.3%)subsequently improved to 93.5 at three months (p = 0.08).
Another much smaller decline was seen at 9 months
(p <0.005), but improved at 12 months and remained
steady, with a score of 94.7 at two years (p = 0.32).Discussion
A variety of treatment modalities for prostate cancer are
available to patients, with retrospective series showing
comparable biochemical local control rates for low-risk
patients treated with surgery, brachytherapy, and exter-
nal beam radiation [41]. However, not all treatment mo-
dalities are appropriate for all patients, and treatment
recommendation decisions are often stratified by patient
convenience and preference, toxicity-related quality of
life, and cancer risk category. Although IMRT is the
standard external beam modality to treat clinically local-
ized prostate cancer, disadvantages include a treatment
course of 8–9 weeks. SBRT delivers highly conformal,
high dose radiation in 5 or fewer treatment fractions,
providing convenience to the patients and a theoretical
improvement in cancer response to larger daily radiation
fractions [6].
A growing body of evidence has established the effi-
cacy of SBRT for prostate cancer treatment, with mul-
tiple single institution studies of SBRT reporting a
biochemical relapse free survival of 90-100% with a me-
dian follow up of 5 years or more [8,10,12,42-45]. In this
SBRT study, our two year biochemical relapse free sur-
vival of a diverse group of low-, intermediate-, and high
risk patients is consistent with that of other institutions.
Table 3 Prevalence of CTC graded GI and GU toxicities
Toxicity Grade Start 1 3 6 9 12 18 24
Diarrhea 0 100% 53% 84% 75% 83% 88% 94% 94%
1 0% 35% 16% 23% 15% 12% 6% 6%
2 0% 12% 0% 2% 2% 0% 0% 0%
Proctitis 0 86% 79% 93% 92% 100% 98% 100% 100%
1 14% 21% 7% 8% 0% 2% 0% 0%
2 0% 0% 0% 0% 0% 0% 0% 0%
Rectal Bleeding 0 100% 91% 95% 100% 98% 98% 96% 96%
1 0% 9% 5% 0% 2% 2% 4% 4%
2 0% 0% 0% 0% 0% 0% 0% 0%
Highest GI 0 67% 46% 77% 75% 82% 86% 91% 91%
1 33% 42% 23% 23% 16% 14% 9% 9%
2 0% 12% 0% 2% 2% 0% 0% 0%
Hematuria 0 98% 95% 93% 94% 91% 90% 91% 94%
1 2% 5% 4% 2% 4% 4% 7% 2%
2 0% 0% 4% 2% 4% 4% 0% 2%
3 0% 0% 0% 2% 2% 2% 2% 2%
Dysuria 0 89% 65% 77% 90% 80% 92% 91% 92%
1 11% 35% 23% 10% 20% 8% 9% 8%
2 0% 0% 0% 0% 0% 0% 0% 0%
Incontinence 0 75% 67% 71% 79% 74% 77% 76% 73%
1 21% 30% 27% 17% 24% 21% 19% 27%
2 4% 4% 2% 4% 2% 2% 6% 0%
Urinary frequency/ urgency 0 39% 16% 55% 62% 48% 52% 48% 58%
1 61% 82% 45% 35% 50% 44% 48% 42%
2 0% 2% 0% 4% 2% 4% 4% 0%
Retention 0 67% 33% 57% 54% 57% 56% 54% 44%
1 33% 26% 20% 21% 19% 15% 19% 29%
2 0% 53% 29% 30% 29% 31% 31% 36%
3 0% 0% 0% 0% 0% 2% 2% 2%
Highest GU 0 33% 5% 25% 32% 26% 32% 32% 37%
1 63% 53% 51% 46% 49% 42% 39% 35%
2 10% 89% 50% 40% 46% 42% 44% 39%
3 0% 0% 0% 2% 2% 2% 4% 4%
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prostates can provide new challenges. Indeed, radiation
treatment of such patients is associated with increased
acute urinary toxicity compared to patients presenting
with small prostates. NCCN guidelines currently recom-
mend caution for brachytherapy treatment of patients
with large prostates based on widely published data relat-
ing the increased frequency of acute urinary obstructive
and irritative symptoms requiring catherization or other
interventions [19,21,22,26,46,47].
The relationship between prostate volume and exter-
nal beam radiation related toxicity has not been aswidely documented, but the correlation between increas-
ing urinary toxicity and increasing prostate volume also
appears to hold true for 3D conformal radiation and
IMRT [31,32]. Pinkawa et al. prospectively assessed health
related quality of life in patients with prostate volumes
stratified by prostate size less than or greater than or equal
to 44 cm3, finding that patients with large prostates had
significantly worse urinary bother scores immediately after
radiation, but that the two groups were not different at 2
and 16 months after treatment [31]. Aizer et al. retro-
spectively reviewed the genitourinary toxicity of patients
treated with IMRT stratified by prostate size into less than
Figure 3 Urinary Toxicity and Quality of Life. a) Cumulative late urinary toxicity (grade 2 in blue and grade 3 in red). b) Average AUA score.
AUA scores range from 0–35 with higher values representing worsening urinary symptoms. c) Percent of patients with urinary symptom flare,
which was defined as having both an AUA score ≥15 with an incrase of ≥5 points above baseline. d) Percent of patients using α-antagonists at
baseline and at different time points at follow up. e-f) Average EPIC urinary irritative/obstructive (e) and incontinence (f) scores. The thresholds
for clinically significant changes in scores (1/2 standard deviation above and below the baseline) are indicated by the red and green lines. EPIC
score range from 0–100 with higher values representing a more favorable health-related quality of life.
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large prostate volumes had significantly higher acute urin-
ary frequency/urgency and grade 3 GU toxicity [32]. There
was no difference between the two groups in urinary re-
tention or incontinence.
In addition to the convenience of the timing of treat-
ment, intra-fraction image guidance during treatmentFigure 4 Gastrointestinal Toxicity and Quality of Life. a) Cumulative lat
Average EPIC bowel domain scores. The thresholds for clinically significant
baseline) are indicated by the red and green lines. EPIC score range from 0
quality of life.allows for smaller CTV-PTV margins, thereby minimiz-
ing dose to nearby critical structures to reduce treatment
related toxicity. SBRT treatment of localized prostate
cancer in patients with large prostates was well tolerated
by patients at our institution. Our largely grade 1–2 tox-
icities were symptomatically managed. If initiation or in-
crease of alpha antagonists was not sufficient to managee gastrointestinal toxicity (grade 2 in blue and grade 3 in red). b)
changes in scores (1/2 standard deviation above and below the
–100 with higher values representing a more favorable health-related
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with symptomatic improvement, as previously reported
[48]. Grade 3 urinary toxicities were infrequent in our
SBRT patients, occurring less commonly than predicted
by the prior large prostate radiation studies using differ-
ent radiation modalities [31,32,49]. When compared to
our previous publication of prostate cancer patients
treated with SBRT not stratified by prostate volume, it
appears that patients with large prostate volumes do
have a higher rate of grade 2 or higher toxicity [7]. Our
results are consistent with those of Pinkawa
and Aizer regarding the trend towards increased acute
irritative obstructive symptoms and toxicity in patients
with large prostates treated with external beam radiation.
Late urinary symptom flares have been commonly ob-
served in prostate cancer patients treated with radiation.
This was first observed by Cesaretti et al. in 2003 as oc-
curring a median of 23.9 months after brachytherapy
[50]. Keyes et al. showed that a greater baseline Inter-
national Prostate Symptom Score was positively corre-
lated with the development of the late urinary symptom
flare [49]. This late urinary symptom flare has also been
described in SBRT [7,9]. While the etiology of the flare is
unknown, theories include late radiation damage to the
smooth muscle or vasculature of the prostate, causing late
radiation induced prostatitis/urethritis. In our patients,
these late urinary symptom flares were observed, and the
majority resolved with conservative management.
Grade 2 or higher GI toxicities were rare in our pa-
tients. Assessment of quality of life showed an acute
worsening of EPIC bowel scores at one month post-
treatment. These findings are comparable to those of
conventionally fractionated radiation therapy [26,51,52],
and the symptoms were managed conservatively with
either observation or medications. To our knowledge,
this is the first study to report a late GI symptom flare
with SBRT. Interestingly, a link between late urinary
symptom flare and rectal toxicity in brachytherapy
patients has been previously described and may relate
to a patient’s ability to repair radiation-induced DNA
damage [49].
Conclusions
We report here, the first study on toxicity and health re-
lated quality of life in patients presenting with large
prostate volumes treated with SBRT. This report sup-
ports the conclusion that patients with larger prostate
volumes can be safely treated with SBRT, and gastro-
intestinal and urinary toxicity rates are comparable, if
not improved, to those observed in conventionally frac-
tionated radiation therapy and brachytherapy. Based on
continued reports on the safety and efficacy of SBRT as
well as patient preference for a shorter treatment course,
SBRT utilization is likely to continue to increase. Ourinstitutional experience adds to the growing body of evi-
dence supporting the effectiveness and safety of SBRT
even for larger prostate volumes.
Consent
Written informed consent was obtained from patients
for the publication of this report and any accompanying
images.
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